Risk adjusted net present value: What is the current valuation of Kissei Pharmaceutical’s Cretostimogene Grenadenorepvec?
Cretostimogene Grenadenorepvec is an oncolytic virus commercialized by Kissei Pharmaceutical, with a leading Phase III program in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).
Cretostimogene Grenadenorepvec is an oncolytic virus commercialized by Kissei Pharmaceutical, with a leading Phase III program in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).
What's Your Reaction?
